APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis
 

• RosuASS provides medium-term annual revenue potential of EUR 2.5 million
• Potential patient group of more than 100,000 individuals
• All three targeted single pill launches realized in 2022

Monheim am Rhein, 6 July 2022. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, is fully on track to achieve its goals. Today, the Single Pill Company announces the rollout of the Single Pill RosuASS in July. With this Single Pill, APONTIS PHARMA addresses the secondary prophylaxis of the group of patients with cardiovascular events in Germany and has thus been able to realize all three targeted market rollouts in financial year 2022. A potential patient group of more than 100,000 people results accordingly for the new Single Pill, which combines the active ingredients rosuvastatin and acetylsalicylic acid (ASA) for the first time on the German market. APONTIS PHARMA anticipates a medium-term annual sales potential for RosuASS of EUR 2.5 million.

Stroke and myocardial infarction are often consequences of high blood pressure and/or disorders of lipid metabolism. Patients who develop a second heart attack or stroke have a significantly increased risk of mortality. Therefore, an important treatment goal for these patients is to prevent a recurrence of a cardiovascular event through appropriate therapeutic measures in so-called secondary prophylaxis. Here, medication usually requires the administration of several different substances, which results in the use of a large number of individual medications. However, as the number of tablets increases, so does the risk that they will not be taken reliably - which in turn increases the risk of a recurrence of heart attack and stroke. With the combination preparation RosuASS, APONTIS PHARMA supports patients' therapy in a far more efficient way.

The clinical relevance of a Single Pill concept has been confirmed by the scientific "START" study, which has been published in peer-reviewed publications such as "Integrated Blood Pressure Control" and "Journal of Comparative Effectiveness Research". In total, data from 59,336 patients who received either a Single Pill or the identical loose combination were included in the analysis of the "START" study. Outcomes of Single Pill therapy included significantly higher treatment adherence, fewer cardiovascular events, lower all-cause mortality, fewer primary care physician visits, and lower total cost per patient.

“Today, we have reached another milestone along our strategy. Including RosuASS, we have succeeded in launching three Single Pills in the current financial year as targeted. By doing so, we are expanding our product portfolio and can offer more effective and cost-saving therapy to the large and steadily growing number of hypertension patients. The Single Pills Tonotec Lipid, AmloAtor and now RosuASS launched in the current financial year have a combined medium-term sales potential of EUR 10.7 million. We have now launched a total of ten Single Pills in the German market and have thus already reached the halfway point towards our medium-term target of 20 Single Pills by 2026,” says Karlheinz Gast, Chief Executive Officer of APONTIS PHARMA AG.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA Presse-Kontakt

CROSS ALLIANCE
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330